Institution Directory

Clinical trials at Northwestern Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1129

Shown on this page

Current sort

Live official records

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin icodec, Insulin glargine, Insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 103
States / cities: Cullman, Alabama • Concord, California • Escondido, California + 85 more

Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
Interventions: GALAD, Liver Ultrasound with or without AFP; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 19
States / cities: Los Angeles, California • Redwood City, California • Roseville, California + 14 more

Conditions: Knee Osteoarthritis, Knee Injuries, Meniscus Tear, Synovitis of Knee, Knee Ligament Injury, Chondral Injury of Left Knee, Chondral Injury of Right Knee, Loose Body Knee
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing, Talazoparib; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 35
States / cities: Duarte, California • Irvine, California • La Jolla, California + 28 more

Conditions: Glioblastoma
Interventions: B-cell vaccination; Biological
Lead sponsor: Catalina Lee Chang; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma
Interventions: Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy; Drug · Radiation · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2037
U.S. locations: 679
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 483 more

Conditions: Spina Bifida, Neurogenic Bowel, Bowel Incontinence
Interventions: Retrograde Enema, Antegrade Enema; Procedure
Lead sponsor: David Chu; Other
Eligibility: 5 Years and older
Enrollment: 943 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Peripheral Artery Disease, Overweight or Obesity
Interventions: Weight loss, Exercise; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Chicago, Illinois • New Orleans, Louisiana • Baltimore, Maryland + 3 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
Interventions: REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 13
States / cities: Duarte, California • Irvine, California • Orange, California + 8 more

Conditions: Refractory Differentiated Thyroid Gland Carcinoma
Interventions: Biospecimen Collection, Cabozantinib, Computed Tomography, Dabrafenib, Magnetic Resonance Imaging, Questionnaire Administration, Trametinib; Procedure · Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 307
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 222 more

Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions: Bevacizumab, Capecitabine, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography; Biological · Drug · Procedure
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 62
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more

Conditions: Cutaneous Melanoma
Interventions: Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Surveillance, Ultrasound Imaging, Wide Local Excision; Procedure · Other · Behavioral
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 75 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 181
States / cities: Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 142 more

About this Northwestern Medicine institution page

What this page lists: ClinicalTrials.gov records that list Northwestern Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Northwestern Medicine

Filter and sort this campus

Live official records

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

National Liver Cancer Screening Trial

Dronabinol After Arthroscopic Surgery

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response

Bowel Continence Across the Lifespan in People With Spina Bifida

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

About this Northwestern Medicine institution page